FOXO4-DRI: What the Research Shows

Research Use Only: This article summarises published scientific literature for laboratory and research audiences. It is not medical advice, and FOXO4-DRI is not approved for human or veterinary use.

What is FOXO4-DRI?

FOXO4-DRI is a designed peptide (a D-retro-inverso variant) studied in the research literature in the context of cellular senescence. It was developed to interfere with a specific protein interaction involving FOXO4 and p53, and it is a well-known research tool in the senolytics field.

Where FOXO4-DRI sits in the research literature

The evidence base is preclinical, based on cell and animal studies of senescent cells. It is frequently used as a research tool to probe senescent-cell biology. Laboratory findings should not be extrapolated to people.

Reported areas of preclinical interest

• FOXO4-p53 interaction: studied as a peptide designed to disrupt this specific interaction in laboratory models.
• Cellular senescence: examined as a senolytic research tool in cell and animal senescence studies.

Why the “research use only” label matters

FOXO4-DRI is supplied as a research material and is intended strictly for laboratory and scientific research, not for human or veterinary consumption.

Handling and storage

Store lyophilised peptide cool, dry and away from light, and refrigerate reconstituted solution, using it within the indicated stability window. Follow the documentation supplied with each batch.

Frequently asked questions

What is FOXO4-DRI studied for?

It is studied as a research tool in cellular-senescence and senolytics research, targeting the FOXO4-p53 interaction in laboratory models.

Is FOXO4-DRI approved for human use?

No. It is a research material only and is not intended for human or veterinary use.

Key takeaways

FOXO4-DRI is a designed peptide widely used as a research tool in senescence and senolytics studies. It is a research material only. Review the FOXO4-DRI research product.

References

References sourced via PubMed.

1. Born E, Lipskaia L, Breau M, et al. Eliminating senescent cells can promote pulmonary hypertension development and progression (FOXO4-DRI senolytic peptide). Circulation. 2023;147(8):650-666. DOI · PubMed 36515093.

Disclaimer: This article is for informational and educational purposes for a research audience. It is not medical advice. Products referenced are sold strictly for laboratory research and are not for human or veterinary use.